Last updated: February 17, 2026
Product Overview:
NDC 70000-0603 corresponds to Everolimus, known commercially as Afinitor. It is an oral kinase inhibitor used for various indications, including renal cell carcinoma, neuroendocrine tumors, and some breast cancers. With approval from the FDA, it holds a significant place in oncology treatment protocols.
Market Size and Growth Potential:
- Current Market Size: The global oncology drug market estimated at USD 208 billion in 2022, with Everolimus representing a niche segment within targeted cancer therapies.[1]
- Sales Data: U.S. sales of Everolimus (Afinitor) in 2022 approached USD 1.1 billion, with growth driven by expanding indications and off-label uses.[2]
- Market Drivers: Increasing prevalence of renal cell carcinoma, neuroendocrine tumors, and breast cancer; clinical trial expansion; higher adoption in combination therapies.
Regulatory Status and Indications:
- FDA Approvals:
- Renal cell carcinoma (advanced)
- Progressive neuroendocrine tumors (carcinoid)
- Hormone receptor-positive, HER2-negative breast cancer (advanced)
- Global Approvals: Market presence in Europe, Japan, and other mature markets, regulated variably by EMA, PMDA, and other agencies.
Competitive Landscape:
- Main Competitors: Sirolimus, Temsirolimus, Everolimus rivals in mTOR inhibition, including generic versions.
- Market Share: Everolimus holds a dominant position among mTOR inhibitors in oncology, but competition from generics and alternative therapies limits pricing power.
Pricing Analysis (Current and Projected):
- Average Wholesale Price (AWP): The retail AWP for a 10 mg dose of Everolimus averages approximately USD 55 per pill in the U.S.[3]
- Monthly Cost: Approximate cost ranges around USD 1,650 per month for a standard 10 mg daily dose.
| Price Metric |
2022 (USD) |
Comments |
| Per pill |
55 |
Retail AWP for 10 mg dose |
| Monthly cost |
1,650 |
Based on daily dosing over 30 days |
| Annual revenue |
13 million |
Per patient, assuming full adherence, in the U.S. |
- Pricing Trends: Slight reductions observed in generic markets; sustained premium in specialty channels.
- Projection for 2025-2030:
- Price Decline: Expected 10-15% reduction in AWP due to generic entry and negotiated discounts.[4]
- Pricing in Emerging Markets: Significantly lower, approximately USD 20-30 per pill, influenced by local reimbursement policies and purchasing power.
Forecasted Market Dynamics:
- Volume Growth: Estimated global sales volume growth of 4-6% annually, driven by higher indications approval and expanding patient pools.
- Price Adjustment Factors: Generic competition, patent cliffs, and value-based pricing models.
- Market Penetration: Increased adoption in combination regimens and off-label uses, pushing volume but pressure on price.
Regulatory and Policy Impact:
- Patent Expiry: U.S. patent expected to expire between 2024-2026, opening domain to generics.[5]
- Pricing Controls: Some countries, such as Germany and Canada, implement strict cost-control measures affecting pricing.
Key Takeaways:
- The market for Everolimus (NDC 70000-0603) has a stable base in oncology with an annual USD 1+ billion sales, with growth driven by expanding indications.
- Price projections suggest moderate declines due to generic competition, with the potential for volume increases offsetting revenue reductions.
- Emerging markets offer lower prices, impacting global revenue distribution.
- Regulatory activity, patent expirations, and health policy changes will influence future pricing and market access.
FAQs
1. What are the primary factors influencing the future price of Everolimus?
Generic entry following patent expiration, market competition, health policy cost controls, and emerging indications impact pricing.
2. How significant is the impact of generic competitors on the market for NDC 70000-0603?
Generics could reduce prices by 50-70% in major markets, leading to substantial revenue shifts, especially from 2024 onward.
3. What is the expected global market growth rate for Everolimus?
An annual growth of approximately 4-6% through 2030, driven mainly by expanding indications and patient access.
4. How do prices vary across international markets?
U.S. prices are higher (~USD 55 per 10 mg pill) due to brand premiums, while emerging markets see lower prices (~USD 20-30 per pill).
5. What strategic actions should pharmaceutical companies consider?
Investing in biosimilars, expanding indications, and early negotiations on pricing can enhance market share amid falling prices.
Citations
[1] Grand View Research. Oncology Drugs Market Size, Share & Trends Analysis Report. 2022.
[2] IQVIA. U.S. Prescription Sales Data. 2022.
[3] GoodRx. Everolimus (Afinitor) Price Comparisons. 2022.
[4] EvaluatePharma. Forecasting Global Oncology Market Trends. 2022.
[5] U.S. Patent and Trademark Office. Patent Status for Everolimus. 2023.
